Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders

Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders

BackgroundThe cytokine interleukin (IL)-1 plays a pivotal role in immune-mediated disorders, particularly in autoinflammatory diseases. Targeting this cytokine proved to be efficacious in treating numerous IL-1-mediated pathologies. Currently, three IL-1 blockers are approved, namely anakinra, canak...

Full description

Bibliographic Details
Main Authors:	Dennis D. Arnold, Ayla Yalamanoglu, Onur Boyman
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-07-01
Series:	Frontiers in Immunology
Subjects:	IL-1 anakinra bermekimab canakinumab gevokizumab rilonacept
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.888392/full

Similar Items

IL-1 Inhibitors in the Treatment of Monogenic Periodic Fever Syndromes: From the Past to the Future Perspectives
by: Hana Malcova, et al.
Published: (2021-02-01)

IL-1 inhibition in systemic juvenile idiopathic arthritis
by: Gabriella Giancane, et al.
Published: (2016-12-01)

The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives
by: Toplak N, et al.
Published: (2018-06-01)

Interleukin-1β inhibitors for the management of acute gout flares: a systematic literature review
by: Naomi Schlesinger, et al.
Published: (2023-07-01)

Management of adult-onset Still’s disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts
by: Serena Colafrancesco, et al.
Published: (2019-12-01)

A Systematic Review of the Safety of Blocking the IL-1 System in Human Pregnancy
by: Marie-Eve Brien, et al.
Published: (2021-12-01)

The efficacy of anti‐IL‐1 targeted therapy in PAPA and PASH syndrome
by: Chloé Challamel, et al.
Published: (2022-09-01)

A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study
by: Antonio Vitale, et al.
Published: (2016-10-01)

Schnitzler syndrome refractory to anakinra: successful treatment with canakinumab
by: Angel Luis Salcedo-Mingoarranz, et al.
Published: (2023-12-01)

An Unusual Case of Allergic Reaction to Anakinra in a Patient with Tumor Necrosis Factor Receptor-1 Associated Periodic Syndrome (TRAPS) and Subsequent Canakinumab Treatment
by: Marta Mejias Trueba, et al.
Published: (2020-07-01)

Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still’s Disease: A Multicentre Retrospective Observational Study
by: Serena Colafrancesco, et al.
Published: (2017-06-01)

Novel Pathophysiological, Diagnostic and Therapeutic Concepts in Acute and Recurrent Pericarditis
by: Aldo Bonaventura, et al.
Published: (2023-03-01)

Therapy resistant urticaria as a long-term symptom of an incomplete Schnitzler syndrome
by: Viktoria Puxkandl, et al.
Published: (2023-07-01)

Clinical efficacy and safety of interleukin-1 blockade in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials
by: Shao-Huan Lan, et al.
Published: (2023-12-01)

Autoinflammatory Diseases and COVID-19 Vaccination: Analysis of SARS-CoV-2 Anti-S-RBD IgG Levels in a Cohort of Patients Receiving IL-1 Inhibitors
by: Sara Bindoli, et al.
Published: (2023-07-01)

Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence
by: Athina Dimosiari, et al.
Published: (2023-02-01)

Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever
by: Ali Şahin, et al.
Published: (2020-01-01)

The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review
by: Véronique Hentgen, et al.
Published: (2020-05-01)

Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders
by: Celine Kaegi, et al.
Published: (2020-03-01)

Interleukin-1 Blockade in Polygenic Autoinflammatory Disorders: Where Are We now?
by: Hana Malcova, et al.
Published: (2021-01-01)

Experiences with IL-1 blockade in systemic juvenile idiopathic arthritis – data from the German AID-registry
by: Elke Lainka, et al.
Published: (2021-03-01)

Failure of anti Interleukin-1 β monoclonal antibody in the treatment of recurrent pericarditis in two children
by: Sara Signa, et al.
Published: (2020-06-01)

Successful treatment of refractory hyperferritinemic syndromes with canakinumab: a report of two cases
by: Riccardo Papa, et al.
Published: (2020-07-01)

Subclinical TRAPS treated with canakinumab
by: M. Amatruda, et al.
Published: (2021-08-01)

Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agents
by: Giorgio Costagliola, et al.
Published: (2021-05-01)

Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
by: Gerd Horneff, et al.
Published: (2017-11-01)

Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide
by: Alessandra Soriano, et al.
Published: (2020-06-01)

The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature
by: Kacar M, et al.
Published: (2020-03-01)

Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders
by: Celine Kaegi, et al.
Published: (2019-09-01)

Systematic review of immunomodulatory therapies for hidradenitis suppurativa
by: Lim SYD, et al.
Published: (2019-05-01)

The IL-1 Antagonist Anakinra Attenuates Glioblastoma Aggressiveness by Dampening Tumor-Associated Inflammation
by: Max Hübner, et al.
Published: (2020-02-01)

Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer
by: Razelle Kurzrock, et al.
Published: (2019-03-01)

Mesothelioma in Familial Mediterranean Fever With Colchicine Intolerance: A Case Report and Literature Review
by: Rosa Talerico, et al.
Published: (2020-05-01)

Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis
by: Jurgen Sota, et al.
Published: (2019-01-01)

Scoping Review on Use of Drugs Targeting Interleukin 1 Pathway in DIRA and DITRA
by: Francisco Gómez-García, et al.
Published: (2018-11-01)

Therapeutic Potential of IL-1 Antagonism in Hidradenitis Suppurativa
by: Laura Calabrese, et al.
Published: (2024-02-01)

Sustained Pericarditis Recurrence Risk Reduction With Long‐Term Rilonacept
by: Massimo Imazio, et al.
Published: (2024-03-01)

Is it possible to extend the dose interval of canakinumab treatment in children with familial Mediterranean fever? PeRA group experience
by: Gülşah Kavrul Kayaalp, et al.
Published: (2023-11-01)

The Role of Interleukin 1β in the Pathogenesis of Lung Cancer
by: Edward B. Garon, MD, et al.
Published: (2020-03-01)

Development of a novel class of interleukin-2 immunotherapies for metastatic cancer
by: Onur Boyman, et al.
Published: (2019-01-01)